Brinzolamide
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Brinzolamide |
| DrugBank ID | DB01194 |
| Brand Names (EU) | Azopt |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.48% |
Approved Indication (EMA)
Decrease of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | primary hereditary glaucoma | 99.48% | DL |
| 2 | open-angle glaucoma | 99.45% | DL |
| 3 | glaucoma 1, open angle | 97.70% | DL |
| 4 | glaucoma | 96.92% | DL |
| 5 | open angle glaucoma | 96.72% | DL |
| 6 | closed-angle glaucoma | 96.60% | DL |
| 7 | hydrophthalmos | 96.55% | DL |
| 8 | commissural lip fistula | 96.00% | DL |
| 9 | osteoradionecrosis of the mandible | 95.93% | DL |
| 10 | burning mouth syndrome | 95.90% | DL |
| 11 | oral leukoedema | 95.90% | DL |
| 12 | oral candidiasis | 95.89% | DL |
| 13 | congenital glaucoma | 95.84% | DL |
| 14 | Axenfeld anomaly | 95.00% | DL |
| 15 | angle-closure glaucoma | 93.93% | DL |
| 16 | aqueous misdirection | 92.65% | DL |
| 17 | traumatic glaucoma | 92.65% | DL |
| 18 | glaucomatous atrophy of optic disc | 91.80% | DL |
| 19 | neovascular glaucoma | 91.70% | DL |
| 20 | salivary gland disease | 90.87% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.